logo
Share SHARE
FONT-SIZE Plus   Neg

4SC Says Its Resminostat Meets Primary Endpoint In Phase II Trial

4SC AG (FSCGF.PK) published encouraging efficacy data from the clinical Phase II SHELTER study with the cancer drug resminostat as a second-line therapy for patients with advanced liver cancer (hepatocellular carcinoma, HCC) who had exhibited radiologically proven tumour progression under first-line therapy with sorafenib prior to study entry.

The open-label, two-arm, international study investigated the safety and efficacy of resminostat both as a monotherapy and in combination with sorafenib for difficult to treat patient group, for which no approved treatment option is currently available.

According to the data now presented, which is based on an advanced data set, the primary study endpoint of halting the further progression of the particularly aggressive cancer in at least 20% of the patients treated and for at least 12 weeks has been achieved ahead of schedule in both therapy arms.

In general, resminostat has proven to be safe and well-tolerated. The most frequent side-effects observed were of a gastrointestinal nature.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Verizon is mulling the acquisition of a big cable company following its rival AT&T's deals with DirecTV and Time Warner, the New York Post reported, citing two well-placed sources. The move is expected to help the firm grow demand for its wireless data products. Saudi Arabian Oil Co., most popularly known as Saudi Aramco, is yet to finalize a date for its long planned initial public offer, but reports said, citing Saudi Arabian officials, that the IPO most likely would be conducted in the second half of 2018. Saudi Aramco Chief Executive Officer Amin Nasser told Bloomberg that the country has promised to reduce the overall tax rate... Dutch semiconductor equipment maker ASML Holding NV reported Wednesday significantly higher profit in its fourth quarter, with higher system sales, selling price and improved margin. Looking ahead, for the first quarter, the company sees sequentially lower net sales and margin.
comments powered by Disqus
Follow RTT